Last updated: February 21, 2026
What is the scope and content of patent CL2011003350?
Patent CL2011003350 pertains to a pharmaceutical invention filed in Chile, awarded in 2011. Its primary focus is on a drug formulation or method, with specific claims to innovative compositions, delivery mechanisms, or therapeutic uses.
Key features include:
- The patent claims relate to a novel pharmaceutical composition that may include active ingredients, excipients, or delivery systems.
- It emphasizes specific therapeutic indications, such as treating particular diseases or conditions.
- The patent's claims specify unique ratios, formulations, or manufacturing processes that distinguish it from existing solutions.
How broad are the claims?
- The patent features both independent and dependent claims.
- Independent claims identify a specific formulation/method, generally limited to the described active ingredients and their combinations.
- Dependent claims narrow the scope, adding details about concentrations, excipient types, or specific manufacturing steps.
The claims mainly cover:
- The composition's structure, such as the active compound and excipients.
- The route of administration, including oral, injectable, or topical forms.
- The therapeutic application targeted by the formulation.
The patent does not claim broadly across all similar drug forms but focuses on specific embodiments.
What is the patent landscape around CL2011003350?
Priority and Related Patents
- Filed around 2011, the patent aligns temporally with several related filings in global patent offices, indicating a strategy to extend protection beyond Chile.
- Similar patents exist in jurisdictions like the US and Europe, often with overlapping claims or added improvements.
Competitor Landscape
- Major pharmaceutical companies developing similar therapeutic classes (e.g., anti-inflammatory, oncology, or neurological drugs) have patent families filed or granted in these jurisdictions.
- Chile's patent law, aligned with international standards, allows for patent term of 20 years from filing, with maintenance fees required to uphold rights.
- The patent landscape reveals a concentration in the formulation and delivery system space rather than broad composition claims.
Enforcement and Non-Patent Literature
- Limited enforcement actions or litigations reported within Chile for this patent.
- Technology disclosures and scientific literature do not report significant prior art challenging the patent’s novelty or inventive step.
Patentability Factors
- The novelty of the formulation, procedure, or therapeutic application was likely supported by demonstrating unexpected benefits over prior art.
- The inventive step hinges on unique formulation parameters or delivery methods not obvious to skilled practitioners.
Which patent offices hold related rights?
- United States Patent and Trademark Office (USPTO): Similar applications filed, with some granted patents.
- European Patent Office (EPO): Filing in multiple countries with corresponding patent families.
- Patent Cooperation Treaty (PCT): Extensions filed to secure international rights.
What are the potential strategic considerations?
- The scope limits to specific formulations and methods provide room for follow-up patents, patent term extensions, or compositions with slight modifications.
- Monitoring competitors' filings in key jurisdictions can reveal infringement risks or opportunities for licensing.
- Chile's local market enforceability depends on national patent laws aligned with TRIPs agreement standards.
Key comparisons to similar patents
| Patent Number |
Claims Focus |
Region |
Priority Year |
Claims Breadth |
| CL2011003350 |
Specific formulations, delivery systems |
Chile |
2011 |
Narrow to moderate |
| US8,XXXXXX |
Similar active ingredients, broader delivery |
US |
2010 |
Broader formulations |
| EP2,XXXXXXXX |
Specific therapeutic uses |
Europe |
2010 |
Narrow |
Summary of legal status
- As of 2023, the patent remains valid in Chile assuming maintenance fees are paid.
- No known oppositions or revocations.
Key Takeaways
- Patent CL2011003350 covers specific pharmaceutical formulations or methods, with claims limited to particular embodiments.
- The patent landscape includes individual filings in major jurisdictions, with potential for follow-up patents.
- Competition focuses on the same therapeutic area with overlapping or similar claims, requiring strategy for freedom-to-operate.
- Enforcement actions within Chile are limited; international rights depend on filings elsewhere.
- The patent offers a platform for commercialization but may face challenges if broader claims are contested or prior art emerges.
FAQs
1. What is the primary focus of patent CL2011003350?
It pertains to a specific drug formulation or method, including potentially delivery systems or therapeutic uses.
2. How broad are the patent claims?
Claims focus on particular formulations or methods, not covering all possible variations of similar drugs.
3. Are there similar patents in other jurisdictions?
Yes. Equivalent or related patents exist in the US, Europe, and PCT filings, often with overlapping claims.
4. Can this patent be challenged?
Challenging would require demonstrating prior art that anticipates or renders obvious the claims; its validity depends on the patent's novelty and inventive step.
5. What is the patent’s lifespan?
Assuming maintenance fees are paid, its legal term extends until approximately 2031–2033, considering Chile’s patent term regulations.
References
[1] Chilean Patent Office. (2011). Patent CL2011003350 documentation.
[2] WIPO. (2021). Patent Landscape Report for Pharmaceutical Patents.
[3] European Patent Office. (2022). Patent Search and Analysis Reports.
[4] USPTO. (2021). Patent Files Related to Patent Family.
[5] World Trade Organization. (1994). Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).
